Response to Sorafenib in a Patient with Metastatic Xp11 Translocation Renal Cell Carcinoma

被引：0

作者：

Ming-Mo Hou

Jia-Juan Hsieh

Nai-Jen Chang

Hsuan-Ying Huang

Hung-Ming Wang

Cheng-Keng Chuang

Todd Hsu

John Wen-Cheng Chang

机构：

[1] Chang Gung University College of Medicine,Division of Haematology

[2] National Taiwan Ocean University,Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital Linkou

[3] Chang Gung University College of Medicine,Institute of Bioscience and Biotechnology and Center for Marine Bioscience and Biotechnology

[4] Chang Gung University College of Medicine,Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital Linkou

[5] Chang Gung University College of Medicine,Department of Pathology, Chang Gung Memorial Hospital

来源：

Clinical Drug Investigation | 2010年 / 30卷

关键词：

Renal Cell Carcinoma; Sorafenib; Sunitinib; Metastatic Renal Cell Carcinoma; Renal Cell Carcinoma Patient;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Sorafenib, a multikinase inhibitor of tumour-cell proliferation and angiogenesis, has been shown to have a role in the treatment of metastatic renal cell carcinoma (RCC). Xp11 translocation carcinoma is a rare subtype of RCC. We report an 18-year-old male patient with metastatic Xp11 translocation RCC who was responsive to sorafenib treatment. Six weeks after commencement of treatment with sorafenib, a CT scan of the patient showed increased central necrosis of the kidney mass and para-aortic lymph nodes as well as regression of the lung and pleural masses. The patient had a progression-free survival of 12 months, and overall survival of 15 months. The most severe adverse effects were grade 3 dermatitis and grade 3 anaemia. This case has demonstrated for the first time that sorafenib is active against Xp11 translocation RCC.

引用

页码：799 / 804

页数：5

共 63 条

[1]

Desangles F.(1999)Translocation (X; 1) associated with a nonpapillary carcinoma in a young woman: a new definition for an Xp11.2 RCC subtype Cancer Genet Cytogenet 113 141-4

[2]

Camparo P.(2003)Five new cases of juvenile renal cell carcinoma with translocations involving Xp 11.2: a cytogenetic and morphologic study Cancer Genet Cytogenet 143 93-9

[3]

Fouet C.(2005)Translocation carcinomas of the kidney Clin Lab Med 25 363-78

[4]

Perot C.(2004)Morphologic and molecular characterization of renal cell carcinoma in children and young adults Am J Surg Pathol 28 1117-32

[5]

Boccon-Gibod L.(2001)Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents Am J Pathol 159 179-92

[6]

Bouvier R.(2007)Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults Am J Clin Pathol 128 70-9

[7]

Argani P.(2009)Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts Am J Surg Pathol 33 1894-901

[8]

Ladanyi M.(2002)Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 289-96

[9]

Bruder E.(2002)PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21) Am J Surg Pathol 26 1553-66

[10]

Passera O.(2003)A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23) Oncogene 22 5374-8

← 1 2 3 4 5 6 7 →